Government Debt Filters Through To The Healthcare Sector

BMI View: The delay in public hospital payments to drugmakers threatens Spain's attractiveness as a location in which to sell drugs and medical devices, especially as public health spending accounts for 7% of total expenditure, which was EUR73.62bn (US$97.65bn) in 2010. In BMI's Pharmaceuticals & Healthcare Business Environment Ratings for Q311, Spain is ranked eighth among the 10 countries surveyed, above only Italy and Portugal.

To read the full article, please choose one of the following options: